



REVIEW

Treatment of epilepsy – towards precision [version 1; referees: 3 approved]

Safe, secure, and specific use of antiepileptic drugs

John Paul Leach

University of Glasgow, Wolfson Medical School Building, Glasgow, Lanarkshire, G12 8QQ, UK

v1 **First published:** 13 Dec 2018, 7(F1000 Faculty Rev):1932 (<https://doi.org/10.12688/f1000research.16448.1>)
Latest published: 13 Dec 2018, 7(F1000 Faculty Rev):1932 (<https://doi.org/10.12688/f1000research.16448.1>)

Abstract

Epilepsy was among the first disease areas to begin to apply principles of precision medicine to its treatment. This review looks at the role of investigation in ensuring the safety and effectiveness of antiepileptic drug treatment. Using sound principles, we can see that the use of genetic testing will advance treatment of epilepsy in reducing harm and adverse effects and enhancing efficacy.

Keywords

Epilepsy, Genetics, Treatment, Safety

Open Peer Review

Referee Status:

	Invited Referees		
	1	2	3
version 1 published 13 Dec 2018			

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **Patrick Kwan**, Monash University, The Alfred Hospital, Australia
- 2 **Pasquale Striano**, Institute "G. Gaslini", University of Genova, Italy
- 3 **Chantal Depondt**, Hôpital Erasme, Université Libre de Bruxelles, Belgium

Discuss this article

Comments (0)

Corresponding author: John Paul Leach (John.Leach@glasgow.ac.uk)

Author roles: Leach JP: Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Leach JP. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Leach JP. **Treatment of epilepsy – towards precision [version 1; referees: 3 approved]** *F1000Research* 2018, 7 (F1000 Faculty Rev):1932 (<https://doi.org/10.12688/f1000research.16448.1>)

First published: 13 Dec 2018, 7(F1000 Faculty Rev):1932 (<https://doi.org/10.12688/f1000research.16448.1>)

Introduction

Epilepsy is one of the most common neurological conditions, affecting around 0.5% to 1% of any given population. It presents a serious health burden, has a recognised (but low) mortality rate, and accounts for 2% to 3% of admissions to acute general medical services.

The outlook for newly diagnosed epilepsy remains good for most people. Around 65% to 70% of patients will attain long-term seizure freedom with the first or second antiepileptic drug (AED) tried¹. In everyday practice, the choice of initial AED on diagnosis currently depends mostly on syndromic classification, the treatment choice being framed by whether the epilepsy is deemed to be genetic generalised or focal in onset². This crude separation of the epilepsies depends on the clinical and sometimes electroencephalography features present at the time of diagnosis.

Publications from the Scottish Intercollegiate Guidelines Network (SIGN 143)³ and the National Institute for Health and Clinical Excellence⁴ have provided clear guidance on many aspects of epilepsy care and have helped guide initial choice of medication and the treatment of refractory epilepsy. After failure of the first drugs, the physician can move to subsequent monotherapy or additional polypharmacy, the choice being largely determined by the likelihood of particular side effects, presence (or otherwise) of concomitant medications, and the presence of or potential for other health conditions in the patient with epilepsy⁵.

Despite the arrival of almost 20 new drugs for epilepsy, the rate of seizure freedom has remained largely unchanged across the decades⁶, and although tolerability may have improved in that time⁷, it becomes clear that we will need to continue to develop more sophisticated ways to determine choice of medication in patients with new-onset or refractory epilepsy.

Some of the motivation for improving specificity and predictability of treatment outcomes becomes clearer with the emergent story of long-term sequelae to exposure to sodium valproate *in utero*. While the biological basis for this adverse effect remains to be clarified, it is vital that the epilepsy community and the regulatory bodies come together to safeguard and promote the use of one of our most effective therapies for genetic generalised epilepsy. Precision medicine has the potential to make epilepsy treatment safer and more effective and it falls to us to ensure that this happens.

Precision medicine and epilepsy

Improving tolerability

Idiosyncratic drug reactions to AEDs are serious but uncommon. One of the most serious complications of carbamazepine (CBZ) use is Stevens–Johnson syndrome, a life-threatening condition that has a mortality rate of around 50% and that develops in around 21 cases per 100,000 patient exposed to CBZ⁸. This idiosyncratic reaction has been shown to be related in some populations to specific HLA markers⁹: HLA-B*1502 is an immunological marker found mainly in patients of Southeast

Asian descent. Its presence is associated in this population with a fourfold increase in the risk of CBZ-associated rash and a 70-fold increase in the risk of Stevens–Johnson syndrome. Such a specific stratification of risk has influenced practice in some patient groups¹⁰ and such work has given us the ability to target CBZ and phenytoin use in specific populations of Southeast Asian descent only to those patients in whom it is safe¹⁰, thereby avoiding increasing risk of harm in patients with newly diagnosed or refractory epilepsy. Such associations are not as firmly correlated for other drugs or in other racial subtypes. The presence of the HLA-A*301 haplotype in those of Northern European descent increases the risk of any form of CBZ-related skin reaction from 5% to 26%¹¹. Calls have been made to promote the cost-effectiveness of screening for this haplotype before CBZ is prescribed in these populations¹².

While such work has helped predict the rarer and serious drug side effects, large ongoing studies of AED use in newly diagnosed epilepsy incorporate genetic testing to try to find genetic associations with less serious but more common side effects of AED use, such as mood disorder, tremor, weight gain, or cognitive change. The mathematical and technical challenges therein are still significant, not least of which will be the clear delineation and definition of these adverse effects and the need to recruit exceptionally large cohorts.

Improving effectiveness

Currently, the choice of treatment in patients with newly diagnosed epilepsy depends on some fairly basic clinical characterisation. The SANAD (Standard and New Antiepileptic Drug) studies from 2007^{7,13} showed the benefits of this, and the two treatment arms were determined by the then-contemporary clinical classification of partial or generalised epilepsy. The choice of treatments was different in each arm in this randomised open study and helped provide a context for drug preference in newly diagnosed epilepsy. In focal epilepsy, the optimal seizure responses were seen with lamotrigine and CBZ, and the former demonstrated somewhat improved tolerability.

The choice of AED for genetic generalised epilepsy has always been more limited since the traditional sodium channel blockers can be associated with an increase in seizure frequency and severity. In the generalised arm of the SANAD study¹³, sodium valproate, rather than topiramate and lamotrigine, was most effective at inducing seizure freedom. However, the deleterious effect of this drug in pregnancy has led to a continued search for safe and efficacious treatment which does not present pregnancy-related problems. The SANAD2 study looks to compare levetiracetam and sodium valproate in patients with newly diagnosed genetic generalised epilepsy and is due to report in 2019.

Given the crude clinical factors that currently influence initial treatment choice, it should be time for principles of precision medicine to come to the fore in our decision making in many stages of epilepsy care. Thankfully this day seems to be closer¹⁴. Genetic studies are becoming increasingly common in patients with epilepsy.

The discovery of a specifically treatable substrate is rare but is potentially life-saving and life-changing, most commonly noted when there is a sodium channel mutation (SCN1A) causing Dravet syndrome or a genetic Glut-1 transporter deficiency (SCL2A1). Such a discovery will firmly place stiripentol¹⁵ or a ketogenic diet¹⁶, respectively, early in the treatment pathway.

The discovery of specific genetic mutations has helped us to repurpose drugs with specific actions which may have been used in entirely unrelated conditions¹⁷. Delineation of a specific channelopathy has allowed us to predict efficacy of quinidine for its antiepileptic effect in patients with epilepsy associated with KCNT1 mutations¹⁸. It may be hoped that further analysis of genetic variations in those with Dravet syndrome will highlight those with serotonergic changes most likely to benefit from new drugs such as the amphetamine derivative fenfluramine, justifying the associated cardiovascular risk¹⁹.

The suggested promise of screening for polymorphisms in p-glycoprotein as a marker or predictor of drug resistance has not been fulfilled in the longer term²⁰, but we should retain hopes of more substantial breakthrough in coming years.

Even where there is no specific targeted treatment currently available, the ability to counsel patients fully or even just provide more insight to affected families will have a markedly positive effect in improving the journey for patients and families²¹.

In adult clinics, genetic analysis in patients with epilepsy is becoming increasingly important, most especially in those patients with associated learning difficulties or progressive encephalopathy or in those with refractory generalised epilepsy. Lindy *et al.*²² reported a positive yield from next-generation sequencing or copy number variation analysis in 15% of patients in a panel of tests looking at up to 70 genes.

Even in early epilepsy, before treatment has been followed up in the long term, genetic testing may shed light on the underlying pathophysiology; around 9% of children with complex febrile convulsions have genetic changes in SCN1A testing²³.

More widespread testing in adult patients can enhance diagnostic yield further. Whole exome sequencing provides a specific diagnosis in 12.5% in patients with non-lesional focal epilepsy with a positive family history²⁴.

Although any patient with refractory epilepsy may benefit from genetic screening, such testing will be of most importance in patients with early-onset seizures (less than 3 years of age), a family history of seizures, associated neurological deficit, or learning disability²⁵. In short, clinical features suggesting widespread neuronal dysfunction are more likely to have an underlying genetic abnormality uncovered by today's testing.




Conclusions

For most of our patients the key to improving outcome remains in the careful electroclinical assessment, allowing full classification and allocation of the most appropriate treatment to invoke the highest chances of seizure freedom and our best attempts at prognostication. Where epilepsy is refractory to treatment or where there is other significant developmental or neurological difficulties, we require careful use of genetic and metabolic testing to fully implement the principles of precision medicine. These principles remain an ideal for other disorders but are becoming a reality for patients with epilepsy. We know that, as genetic technologies advance, this will become an increasingly important part of management, not only for our patients with refractory or complex epilepsy but even in those whose epilepsy is newly diagnosed. In such uncertain times, we know that our epilepsy clinics will require us to be able to relate to complex genetics as they unfold but more importantly to be able to relate to our patients and their families. As they progress through their life journey with its challenges, they need a clinician with the knowledge, experience, and wisdom to interpret the genetic findings.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1.  Chen Z, Brodie MJ, Liew D, *et al.*: **Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study.** *JAMA Neurol.* 2018; 75(3): 279–86. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
2.  Scheffer IE, Berkovic S, Capovilla G, *et al.*: **ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.** *Epilepsia.* 2017; 58(4): 512–21. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
3. Scottish Intercollegiate Guidelines Network: **Diagnosis and management of epilepsy in adults.** SIGN guideline no. 143, 2015, updated 2018. [Reference Source](#)
4. National Institute for Health and Clinical Excellence: **The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care: Pharmacological Update of Clinical Guideline 20.** NICE clinical guideline 137. London: NICE, 2012; Accessed 12th September 2018]. [PubMed Abstract](#)
5. Leach JP: **When the antiepileptic drugs are not working.** *Pract Neurol.* 2009; 9(1): 27–32. [PubMed Abstract](#) | [Publisher Full Text](#)
6.  Brodie MJ: **Outcomes in newly diagnosed epilepsy in adolescents and adults: Insights across a generation in Scotland.** *Seizure.* 2017; 44: 206–10. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
7. Marson AG, Al-Kharusi AM, Alwaidh M, *et al.*: **The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.** *Lancet.*



- 2007; 369(9566): 1000–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. **F** Frey N, Bodmer M, Bircher A, *et al.*: **The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs.** *Epilepsia*. 2017; 58(12): 2178–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 9. **F** Sukasem C, Chaichan C, Nakkrut T, *et al.*: **Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.** *J Immunol Res*. 2018; 2018: 2780272.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 10. **F** Phillips EJ, Sukasem C, Whirl-Carrillo M, *et al.*: **Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.** *Clin Pharmacol Ther*. 2018; 103(4): 574–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 11. **F** McCormack M, Alfievic A, Bourgeois S, *et al.*: **HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.** *N Engl J Med*. 2011; 364(12): 1134–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 12. Plumpton CO, Yip VL, Alfievic A, *et al.*: **Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy.** *Epilepsia*. 2015; 56(4): 556–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
 13. Marson AG, Al-Kharusi AM, Alwaidh M, *et al.*: **The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.** *Lancet*. 2007; 369(9566): 1016–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 14. Berkovic SF: **Genetics of Epilepsy in Clinical Practice.** *Epilepsy Curr*. 2015; 15(4): 192–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. **F** Myers KA, Lightfoot P, Patil SG, *et al.*: **Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study.** *Dev Med Child Neurol*. 2018; 60(6): 574–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 16. Ramm-Petersen A, Nakken KO, Skogseid IM, *et al.*: **Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study.** *Dev Med Child Neurol*. 2013; 55(5): 440–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. **F** Striano P, Vari MS, Mazzocchetti C, *et al.*: **Management of genetic epilepsies: From empirical treatment to precision medicine.** *Pharmacol Res*. 2016; 107: 426–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 18. Mikati MA, Jiang YH, Carboni M, *et al.*: **Quinidine in the treatment of KCNT1-positive epilepsies.** *Ann Neurol*. 2015; 78(6): 995–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 19. **F** Polster T: **Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.** *Epilepsy Behav*. 2018; pii: S1525-5050(18)30405-0.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 20. **F** Balestrini S, Sisodiya SM: **Pharmacogenomics in epilepsy.** *Neurosci Lett*. 2018; 667: 27–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 21. Brunklaus A, Dorris L, Ellis R, *et al.*: **The clinical utility of an SCN1A genetic diagnosis in infantile-onset epilepsy.** *Dev Med Child Neurol*. 2013; 55(2): 154–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. **F** Lindy AS, Stosser MB, Butler E, *et al.*: **Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders.** *Epilepsia*. 2018; 59(5): 1062–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 23. Symonds JD, Lang B, Vincent A, *et al.*: **Genetic and immune findings in complex febrile seizures and the epidemiology of Dravet syndrome: A nationwide cohort study.** *Eur J Paediatr Neurol*. 2017; 21(Supplement 1): e168.
[Publisher Full Text](#)
 24. **F** Perucca P, Scheffer IE, Harvey AS, *et al.*: **Real-world utility of whole exome sequencing with targeted gene analysis for focal epilepsy.** *Epilepsy Res*. 2017; 131: 1–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 25. **F** Ortega-Moreno L, Giráldez BG, Soto-Insuga V, *et al.*: **Molecular diagnosis of patients with epilepsy and developmental delay using a customized panel of epilepsy genes.** *PLoS One*. 2017; 12(11): e0188978.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Referee Status:



Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- Chantal Depondt** Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
Competing Interests: No competing interests were disclosed.
- Pasquale Striano** Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences and Rehabilitation, Institute "G. Gaslini", University of Genova, Genova, Italy
Competing Interests: No competing interests were disclosed.
- Patrick Kwan** Departments of Neuroscience and Neurology, Central Clinical School, Monash University, The Alfred Hospital, Melbourne, Victoria, 3004, Australia
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research